One GI®, the leading network of independent gastroenterology practices, today announced a strategic partnership with Oshi Health, the nation’s only nationwide virtual multidisciplinary GI clinic, through Oshi’s Access+ program. With Oshi, One GI practices can quickly and easily expand clinical offerings and reduce administrative burden, improving their overall financial health and achieving better patient outcomes. As part of the agreement, One GI practices can access GI-trained Oshi Health Advanced Practice Providers (APPs) as dedicated, full-time virtual staff to extend clinical capacity. Practices’ front desk teams can manage these APPs’ schedules, with physicians maintaining oversight of every patient interaction. With Oshi,…
Author: Abhay Panchal
At the Cleveland Clinic, the newly formed Endorobotics Collaborative signals a shift in how innovation in gastroenterology is being built—not as isolated device development, but as a fully integrated ecosystem spanning clinicians, engineers, and industry partners. The core problem is clear: as endoscopic procedures become more complex—approaching surgical-level interventions—current endoscopes lack stability, triangulation, and ergonomics, making advanced procedures technically demanding, time-intensive, and limited to a small group of highly skilled operators. This creates a bottleneck in access, despite clear clinical benefits of minimally invasive approaches. The Collaborative is designed to solve that gap by acting as a “bench-to-bedside” development engine—supporting…
Researchers led by Animesh Acharjee at the University of Birmingham have identified overlapping microbial and metabolite patterns in stool samples that can predict multiple gastrointestinal diseases—not just one. Across large datasets, signals linked to gastric cancer, colorectal cancer, and inflammatory bowel disease (IBD) were not isolated. Instead, patterns from one condition often helped predict another. The strongest crossover was seen from gastric cancer signals pointing toward IBD, while colorectal cancer signals more often mapped back to gastric cancer—suggesting non-random biological connections across GI diseases. What makes this meaningful is not just detection—but shared biology. The predictive power didn’t come from…
The American Gastroenterological Association (AGA) has awarded $2.9 million to 84 researchers, reinforcing its long-standing role in shaping the future of digestive health through early-stage funding and talent development. On the surface, this looks like a routine grant cycle. But the structure tells a deeper story: the funding spans basic science, translational research, cancer, IBD, celiac disease, and early-career investigator programs, signaling a deliberate effort to build a diversified innovation pipeline across the GI ecosystem. Importantly, a significant portion of these awards targets career transitions (fellow-to-faculty), pilot studies, and student-level research, which is where many high-impact ideas are first de-risked.…
Gastroenterologists in the US are facing mounting pressures to see and scope more patients. The clinical demands of an aging population, together with increased endoscopic volumes driven by the surge in early-onset colon cancer, continue to outpace the available workforce. In response, many health care systems are turning to the GI hospitalist (GIH) model: gastroenterologists hired to work exclusively in the hospital to manage inpatient consultations, perform urgent and emergent endoscopies, coordinate multidisciplinary care, and streamline hospital operations. What began as a pragmatic staffing solution has evolved into a distinct and rewarding career track — one that enriches fellowship training, alleviates key pain points for…
A prospective study on virtual multidisciplinary GI care is challenging the assumption that complex gastrointestinal conditions require fragmented, in-person management. In a cohort of 234 patients with IBS and related disorders, a fully virtual care model—combining gastroenterologists, dietitians, psychologists, and health coaches—delivered significant improvements in symptom control, quality of life, and patient satisfaction, while also driving meaningful operational efficiency. Engagement was high (80%), with patients accessing care quickly (average wait: 6 days) and interacting across multiple specialties. The clinical impact was substantial: symptom control rates rose from ~20% to 86%, alongside marked reductions in symptom severity and improvements in productivity.…
A new validation study of the American Society for Gastrointestinal Endoscopy (ASGE) complexity grading system confirms something clinicians intuitively know: not all endoscopic procedures are created equal. For procedures like EGD, colonoscopy, and EUS, the grading system shows strong correlation with both physician effort (wRVUs) and medicolegal risk (mRVUs)—suggesting it is a reliable framework for measuring procedural difficulty.
Sixty-five adults with IBS-D were randomized to LFD or rifaximin for 5 weeks. Primary endpoints were changes in mean daily abdominal pain and bloating at week 5 versus baseline. Secondary endpoints included changes in IBS Symptom Severity Score (IBS-SSS) and Bristol Stool Form Scale (BSFS) at week 5 versus baseline. Exploratory endpoints included responders defined as ≥30% reduction in abdominal pain or bloating. Stool samples collected at weeks 0, 2, 4, and 5 underwent 16S rRNA sequencing, and glucose breath testing (BT) was performed at weeks 0 and 5.
A large Cochrane review is challenging one of the most persistent assumptions in preventive gastroenterology: that aspirin meaningfully reduces colorectal cancer (CRC) risk in average-risk populations. Across nearly 125,000 participants from randomized trials, aspirin showed little to no impact on CRC incidence over 5–15 years, with any potential benefit appearing only after more than a decade—and even then, the evidence remains uncertain.
The gut microbiome was once a niche concept, but now is a mainstream health concept and rapidly gaining ground as a business opportunity. With more research connecting gut health and conditions such as digestion and mental health, microbiome companies are moving quickly to convert research into services and products. With the consumer demand for personalised health, this has created what is described as the ‘gold-rush’ of microbiome research.